# Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/anlotinib-combined-with-pd-1-blockade-for-the-treatment-of-lung-cancer-a-real/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Xiangyu Zhang,Liang Zeng,Yizhi Li,Qinqin Xu,Haiyan Yang,Analyn Lizaso,Xinru Mao,Renan Jin,Yu Zeng,Qinglin Li,Jianbo Wang,Li Yang,Yongchang Zhang,Nong Yang |
| Citations | 64 |
| DOI | 10.1007/s00262-021-02869-9 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/10991983 |
| OpenAlex ID | https://openalex.org/W3128973972 |
| PMID | 33566148 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Haiyan Yang](https://scholariq.org/researchers/haiyan-yang/)
- [Yongchang Zhang](https://scholariq.org/researchers/yongchang-zhang/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.